Castle Biosciences, Inc. (CSTL) Q4 2023 Earnings Call Transcript

Castle Biosciences, Inc. (NASDAQ:CSTL) Q4 2023 Earnings Conference Call February 28, 2024 4:30 PM ET

Company Participants

Camilla Zuckero - VP, IR & Corporate Affairs
Derek Maetzold - President, CEO, Founder & Director
Frank Stokes - CFO

Conference Call Participants

Kyle Mikson - Canaccord Genuity
Brandon Kramer - Guggenheim Securities
Sung Ji Nam - Scotiabank
Tom Peterson - Baird
Jacob Krahenbuhl - Stephens
Thomas Flaten - Lake Street

Operator

Good afternoon, and welcome to Castle Biosciences Fourth Quarter and Full Year 2023 Conference Call. As a reminder, today's call is being recorded. We will begin today's call with opening remarks and introductions followed by a question and answer session.

I would now like to turn the call over to Camilla Zuckero, Vice President, Investor Relations and Corporate Affairs. Please go ahead.

Camilla Zuckero

Thank you, operator. Good afternoon, everyone. Welcome to Castle Biosciences fourth-quarter and full year 2023 financial results conference call. Joining me today is Castle's Founder, President, and Chief Executive Officer, Derek Maetzold, and Chief Financial Officer, Frank Stokes.

Information recorded on this call speaks only as of today, February 28, 2024. Therefore, if you are listening to the replay or reading the transcript of this call, any time-sensitive information may no longer be accurate. A recording of today's call will be available on the Investor Relations page of the company's website for approximately three weeks following the conclusion of the call.

Before we begin, I would like to remind you that some of the statements made today will contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our financial outlook; ; and similar items referenced in our earnings release issued today, and statements containing projections regarding future events or our future financial or operational performance, including our anticipated